4D Molecular Therapeutics’ (FDMT) Sell (E+) Rating Reiterated at Weiss Ratings
Weiss Ratings reissued their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research note released on Saturday morning,Weiss Ratings reports. A number of other analysts have also recently commented on the stock. Bank of America cut their price target on shares of 4D Molecular Therapeutics from $42.00 to […]
13 May 05:16 · The Markets Daily